» Articles » PMID: 28893776

Mycobacterium Tuberculosis Subculture Results in Loss of Potentially Clinically Relevant Heteroresistance

Overview
Specialty Pharmacology
Date 2017 Sep 13
PMID 28893776
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Multidrug-resistant tuberculosis (TB) presents a major public health dilemma. Heteroresistance, the coexistence of drug-resistant and drug-susceptible strains or of multiple drug-resistant strains with discrete haplotypes, may affect accurate diagnosis and the institution of effective treatment. Subculture, or passage of cells onto fresh growth medium, is utilized to preserve cell lines and is universally employed in TB diagnostics. The impact of such passages, typically performed in the absence of drug, on drug-resistant subpopulations is hypothesized to vary according to the competitive costs of genotypic resistance-associated variants. We applied ultradeep next-generation sequencing to 61 phenotypically rifampin-monoresistant ( = 17) and preextensively ( = 41) and extensively ( = 3) drug-resistant isolates with presumptive heteroresistance at two time points in serial subculture. We found significant dynamic loss of minor-variant resistant subpopulations across all analyzed resistance-determining regions, including eight isolates (13%) whose antibiogram data would have transitioned from resistant to susceptible for at least one drug through subculture. Surprisingly, some resistance-associated variants appeared to be selected for in subculture.

Citing Articles

Xpert MTB/RIF Ultra-resistant and MTBDRsusceptible rifampicin results in people with tuberculosis: utility of FluoroType MTBDR and deep sequencing.

Ghebrekristos Y, Ahmed A, Beylis N, Singh S, Opperman C, Naufal F Antimicrob Agents Chemother. 2025; 69(3):e0167124.

PMID: 39918315 PMC: 11881552. DOI: 10.1128/aac.01671-24.


Genetic stability of under the stress of first-line antitubercular agents.

Molnar D, Suranyi E, Trombitas T, Fuzesi D, Hirmondo R, Toth J Elife. 2024; 13.

PMID: 39565350 PMC: 11578590. DOI: 10.7554/eLife.96695.


Molecular characteristics of drug-susceptible Mycobacterium tuberculosis clinical isolates based on treatment duration.

Ko E, Min J, Kim H, Jeong J, Lee S, Kim S Osong Public Health Res Perspect. 2024; 15(5):385-394.

PMID: 39511960 PMC: 11563727. DOI: 10.24171/j.phrp.2024.0101.


Impact of heteroresistance on treatment outcomes of people with drug-resistant TB.

Crowder R, Kato-Maeda M, Schwem B, Dela Tonga A, Geocaniga-Gaviola D, Lopez E IJTLD Open. 2024; 1(10):466-472.

PMID: 39398438 PMC: 11467852. DOI: 10.5588/ijtldopen.24.0343.


Sequencing by binding rivals SMOR error-corrected sequencing by synthesis technology for accurate detection and quantification of minor (< 0.1%) subpopulation variants.

Allender C, Wike C, Porter W, Ellis D, Lemmer D, Pond S BMC Genomics. 2024; 25(1):789.

PMID: 39160478 PMC: 11331594. DOI: 10.1186/s12864-024-10697-1.


References
1.
Gagneux S, Long C, Small P, Van T, Schoolnik G, Bohannan B . The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science. 2006; 312(5782):1944-6. DOI: 10.1126/science.1124410. View

2.
Gillespie S . Antibiotic resistance in the absence of selective pressure. Int J Antimicrob Agents. 2001; 17(3):171-6. DOI: 10.1016/s0924-8579(00)00340-x. View

3.
Domenech P, Reed M . Rapid and spontaneous loss of phthiocerol dimycocerosate (PDIM) from Mycobacterium tuberculosis grown in vitro: implications for virulence studies. Microbiology (Reading). 2009; 155(Pt 11):3532-3543. PMC: 5154741. DOI: 10.1099/mic.0.029199-0. View

4.
Mitchison D . Tests for streptomycin sensitivity of tubercle bacilli in tween 80 albumin liquid medium. Lancet. 1949; 2(6581):694-6. DOI: 10.1016/s0140-6736(49)91327-6. View

5.
Farhat M, Jacobson K, Franke M, Kaur D, Sloutsky A, Mitnick C . Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis. J Clin Microbiol. 2016; 54(3):727-33. PMC: 4767988. DOI: 10.1128/JCM.02775-15. View